ArticleCardiovascular research2025
Impaired coronary flow reserve by hyperviscosity in a mouse model of non-light chain multiple myeloma: a mechanism of coronary flow impairment at the capillary level.
Article in Cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The year in cardiovascular medicine 2025: the top 10 papers in cardio-oncology.European heart journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsMultiple myeloma (MM) is associated with cardiovascular risk, although the exact underlying mechanisms are unknown. Here, we tested the hypothesis that MM impairs coronary flow reserve (CFR) due to increased blood viscosity caused by elevated monoclonal protein concentration. METHODS AND
resultsIn a mouse Vĸ*MYC model of non-light chain MM recapitulating all aspects of human disease, we showed that the disease progression was associated with progressive increase of blood and plasma viscosity. Using intravital microscopy imaging of ex vivo stained red blood cells, we observed reduction of CFR in vivo with the CFR limiting site being coronary capillaries. This was further confirmed by similar coronary flow profile in mice with hyperviscosity induced by acute hyperlipidaemia and disappearance of this MM-related CFR impairment in saline perfused ex vivo hearts. Of note, nitric oxide production in vivo was increased in the coronary circulation, especially at the capillary level, but the systemic concentration of nitric oxide metabolites was unchanged, again supporting the hypothesis that increased blood viscosity is the main culprit here. Moreover, MM progression was associated with progressive impairment of left and right ventricular function, but without histological signs of myocardial deterioration, hypertrophy, or fibrosis.
conclusionOur study shows a potentially completely new mechanism of cardiovascular adverse effects caused by MM or more broadly by hyperviscosity syndromes, i.e. CFR impairment at the capillary level. Since capillaries, unlike larger vessels, cannot be recanalized or dilated, completely new preventive approaches are needed, such as agents affecting blood rheology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.